Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-28T11:50:07.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-Effectiveness of Hepatitis-B Vaccine in Greece: A Country of Intermediate HBV Endemicity

Published online by Cambridge University Press:  10 March 2009

Evi J. Hatziandreu ,
Angelos Hatzakis ,
Stefanos Hatziyannis ,
Mark A. Kane  and
Milton C. Weinstein
Evi J. Hatziandreu
Affiliation:
Harvard School of Public Health
Angelos Hatzakis
Affiliation:
Athens University School of Medicine
Stefanos Hatziyannis
Affiliation:
Athens University School of Medicine
Mark A. Kane
Affiliation:
Centers for Disease Control
Milton C. Weinstein
Affiliation:
Harvard School of Public Health
Get access Rights & Permissions [Opens in a new window]

Abstract

We evaluated the cost-effectiveness of (a) a vaccination program for the prevention of hepatitis B; and (b) the two commercially available vaccines (Merck Sharp and Dohme; Pasteur Institute) in Greece, a country of intermediate endemicity. We examined cases of hepatitis-B infection prevented and the expected medical costs among the high-risk groups of medical and nursing students, hospital personnel, and the general population. Employing a vaccination program reduces considerably the risk of infection, especially in the high-risk groups, while it increases the total cost. The vaccines are very comparable in terms of both health and economic outcomes. Sensitivity analysis indicated that vaccine cost, incidence of hepatitis B, and compliance were the key factors for the choice of (a) whether to undertake an extensive program to prevent hepatitis-B infection and its chronic sequelae; and (b) which vaccine to administer.

Type
Special Section: Assessment Of Preventive Technologies
Information
International Journal of Technology Assessment in Health Care , Volume 7 , Issue 3 , Summer 1991 , pp. 256 - 262
Copyright
Copyright © Cambridge University Press 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Davies, G. N.Cost and benefit of fluoride in the prevention of dental caries. WHO Bulletin, 1974, 9, 91.Google Scholar
2.Francis, D. P.Selective primary health care; strategies for control of disease in the developing world: Hepatitis B virus and its related diseases. Review of Infectious Diseases, 1983, 5, 322-29.CrossRefGoogle ScholarPubMed
3.Jonsson, B.Cost-benefit analysis of hepatitis B vaccination. Postgraduate Medical Journal, 1987, 63, 27–32.Google ScholarPubMed
4.Hatziyannis, S., Hatzakis, A., Anastasakos, C, & Trichopoulos, D. A randomized clinical trial of two commercially available hepatitis B vaccines (abstract). 10th Annual Panhellenic Medical Conference, Athens, 05 1984.Google Scholar
5.Hatziyannis, S., Papaioannou, C, Hatzakis, A., et al. HBV vaccination of hospital personnel: Three year follow-up (abstract). 12th Annual Panhellenic Medical Conference, Athens, 05 1986.Google Scholar
6.Hatziyannis, S., Papaioannou, C., Hatzakis, A., et al. Long-term immunogenicity and efficacy of two plasma-derived HB vaccines: Results of a randomized trial in hospital personnel. European Symposium of Hepatitis B Immunization: Evaluation and Perspectives (abstract). Rome, 10 1986.Google Scholar
7.Hatzakis, A., Anastasakos, C., & Hatziyannis, S.Hepatitis B vaccination (letter). Lancet, 1982, ii, 1457–58.Google Scholar
8.Hatzakis, A., Hatziyannis, S., Anastasakos, C., et al. Risk of hepatitis B infection in hospital personnel and priority setting for HBV vaccination. Iatriki, 1984, 46, 157–65.Google Scholar
9.Hatziandreu, E. J., Koplan, J. P., Weinstein, M. C, et al. A cost-effectiveness analysis of exercise as a health promotion activity. American Journal of Public Health, 1988,78,1417–21CrossRefGoogle ScholarPubMed
10.Koplan, J. P., & Axnick, N. W.Benefits, risks, and costs of viral vaccines. Program Medical Virology, 1982, 28, 180–91.Google ScholarPubMed
11.Lahaye, D., Baleux, C., Strauss, P., & Van Ganse, W.Cost-benefit analysis of hepatitis B vaccination. Lancet, 1987, ii, 441–43.CrossRefGoogle Scholar
12.Maynard, J. E., Kane, M. A., & Hadler, S. C. Global control of hepatitis B through vaccination: The role of hepatitis B vaccination in the expanded programme on immunization. Review of Infectious Diseases, in press.Google Scholar
13.Mulley, A. G., Silverstein, M. D., & Dienstag, J. L.Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. New England Journal of Medicine, 1982, 307, 644–52.CrossRefGoogle ScholarPubMed
14.WHO Weekly Epidemiological Record, 03 25, 1988, 63, 89–96.Google Scholar